{
    "clinical_study": {
        "@rank": "119157", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo arm"
            }, 
            {
                "arm_group_label": "Verum", 
                "arm_group_type": "Active Comparator", 
                "description": "Verum arm - Pascoflair 425mg"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, double blind, placebo-controlled pilot study on the efficacy of Passiflora\n      incarnata L. in an acute stressful situation"
        }, 
        "brief_title": "Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST)", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Stress"
        ], 
        "detailed_description": {
            "textblock": "Randomized, double-blind, placebo-controlled, single-center study During Visit 1 study\n      information and an informed consent form are handed out. After study inclusion on Visit 2,\n      participants are assigned to one of two groups at random and receive the test products\n      (either Pascoflair\u00ae or placebo tablets). The 3rd visit includes the completion of\n      questionnaires regarding wellbeing and the Trier Social Stress Test."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent;\n\n          -  Healthy male and female subjects\n\n          -  Non-smoker;\n\n          -  Age 25 to 45 years;\n\n          -  BMI \u2265 19 to \u2264 30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any known allergies to the test substance;\n\n          -  Any known addiction to drugs, alcohol or positive results in the drug       screening\n             test;\n\n          -  Any serious general illness, ongoing or within the last 12 months;\n\n          -  Any febrile illness (> 24 hrs.) within 7 days prior to treatment;\n\n          -  Any antibiotics for the last four weeks before study inclusion;\n\n          -  Diabetes mellitus;\n\n          -  Known heart disease, hypertension, kidney disease, significant respiratory disease,\n             epilepsy, or rheumatoid arthritis;\n\n          -  Known immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS)\n             which could place the subject at risk or interfere with the accuracy of the study\n             results;\n\n          -  Pregnancy or lactating;\n\n          -  Current participation or participation in any type of clinical study in the past\n             week;\n\n          -  Current or past participation in a TSST study;\n\n          -  Employees of the Sponsor or the CRO;\n\n          -  Any other medication that, in the opinion of the Investigator is likely to affect\n             their response to treatment;\n\n          -  Clinically relevant abnormalities in physical examinations, vital signs, clinical\n             chemistry, or haematology as judged by the Investigator;\n\n          -  Any other condition the Investigator or their duly assigned representatives believes\n             may affect the ability of the individual to complete the study or the interpretation\n             of the study results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665170", 
            "org_study_id": "178 S11 PF", 
            "secondary_id": "2011-006129-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Verum", 
                "description": "3 x 1 tablet per day for 3 days", 
                "intervention_name": "Passiflora incarnata", 
                "intervention_type": "Drug", 
                "other_name": "Pascoflair 425mg coated tablets"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "3 x 1 ablet per day for 3 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pascoflair", 
            "tsst", 
            "passiflora incarnata", 
            "non smoking male", 
            "and female volunteers"
        ], 
        "lastchanged_date": "August 24, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Trier", 
                    "country": "Germany", 
                    "zip": "54296"
                }, 
                "name": "Juliane Hellhammer"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo-controlled Pilot Study on the Efficacy of Passiflora Incarnata L. in an Acute Stressful Situation", 
        "overall_official": {
            "affiliation": "Klinikum Mutterhaus der Borrom\u00e4erinnen GmbH, Feldstr. 16, 54290 Trier", 
            "last_name": "Michael Clemens, MD, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objective is to assess effects of P. incarnata on psychological stress measured by Visual Analogue Scales (VAS; Bond and Lader 1974) by comparing scores collected before, during and after stress exposure between the P. incarnata and a placebo group. In this study, psychological stress is defined as stress perception, anxiety and insecurity. These three variables are determined simultaneously in the study before, during and after the stress test.", 
                "measure": "VAS insecurity", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The primary objective is to assess effects of P. incarnata on psychological stress measured by Visual Analogue Scales (VAS; Bond and Lader 1974) by comparing scores collected before, during and after stress exposure between the P. incarnata and a placebo group. In this study, psychological stress is defined as stress perception, anxiety and insecurity. These three variables are determined simultaneously in the study before, during and after the stress test.", 
                "measure": "VAS anxiety", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The primary objective is to assess effects of P. incarnata on psychological stress measured by Visual Analogue Scales (VAS; Bond and Lader 1974) by comparing scores collected before, during and after stress exposure between the P. incarnata and a placebo group. In this study, psychological stress is defined as stress perception, anxiety and insecurity. These three variables are determined simultaneously in the study before, during and after the stress test.", 
                "measure": "VAS stress perception", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "will be collected 2 min. prior to the stress test and 1, 10, 20, 30, 45 and 60 min. after the TSST", 
                "measure": "Saliva cortisol", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "2 min. prior to and 1 min. after the TSST", 
                "measure": "Serum cortisol", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "ACTH - Adrenocorticotropes Hormon - 2 min. prior to and 1 min. after the TSST", 
                "measure": "ACTH", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "2 min. prior to and 1 min. after the TSST", 
                "measure": "Epinephrine", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "2 min. prior to and 1 min. after the TSST", 
                "measure": "Norepinephrine", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The STAI-X1 measures state anxiety (one scale). Answers are given on a four-point rating scale ranging from 1 = \"not at all\" to 4 = \"very true\". The questionnaire is used as baseline measurement at V2. In addition, it is also employed before and immediately after the stress test at V3 to assess changes in state anxiety. Assess V2, before and after V3", 
                "measure": "State anxiety (STAI-X1) Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The POMS assesses the four states depression/anxiety, fatigue, vigor and hostility (4 scales). High vigor scores reflect a positive mood whereas high scores in the other subscales indicate negative mood. Subjects rate their mood state on a 7-point rating scale ranging from 1 = \"not at all\" to 7 = \"very strongly\". The questionnaire is completed on V2 and V3.", 
                "measure": "POMS Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The MDBF assesses the three bipolar dimensions good/bad mood, wakefulness/tiredness and calmness/agitation (3 scales). The short form of the MDBF and its parallel version (versions A and B) each consist of 12 items. Subjects rate their mood state on a 5-point rating scale ranging from 1 = \"not at all\" to 5 = \"very true\". To determine mood changes induced by the TSST, the questionnaire is completed shortly before (version A) and immediately after the TSST (version B). Assess before and after V3", 
                "measure": "MDBF Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The LSEQ investigates four aspects of sleep using VAS: getting to sleep, quality of sleep, awakening from sleep and behavior following awakening. The LSEQ is completed on V2 and V3.", 
                "measure": "LSEQ Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }
        ], 
        "source": "Pascoe Pharmazeutische Praeparate GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "Daacro", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pascoe Pharmazeutische Praeparate GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}